PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis

X Cheng, RL Bennett, X Liu, M Byrne and W Stratford May

Reduced expression and activity of the proapoptotic, double-stranded RNA-dependent protein kinase, PKR (protein kinase R) is observed in breast, lung and various leukemias, suggesting that loss of PKR potentiates transformation. Now we report that decreased PKR activity inhibits chemotherapy-induced apoptosis of leukemia cells both in vitro and in vivo. Inhibition of PKR expression or activity reduces protein phosphatase 2A (PP2A) activity, a B-cell lymphoma 2 (Bcl-2) phosphatase, resulting in enhanced Bcl-2 phosphorylation. Thus, inhibition of PKR activity leads to hyperphosphorylation of Bcl-2, stabilization of Bcl-2/Bax interaction and decreased Bax insertion into the outer mitochondrial membrane. Treatment with the PP2A activator, FTY720, restores Bcl-2 dephosphorylation and apoptosis in cells with reduced PKR expression following stress. Significantly, xenografts of REH leukemic cells with reduced PKR display significantly increased tumor volume, increased resistance to doxorubicin treatment and shorter survival. Importantly, FTY720 treatment restores sensitivity to chemotherapy and prolongs overall survival of these mice. Collectively, these findings suggest that PP2A activation is a downstream target of PKR and the PKR/PP2A signaling axis is required for rapid and potent stress-induced apoptosis. Importantly, loss of PKR promotes leukemia progression and may serve as a biomarker for predicting chemosensitivity.

**Blood Cancer Journal (2013) 3, e144; doi:10.1038/bcj.2013.42; published online 6 September 2013**

**Keywords:** leukemia; PKR; apoptosis; Bcl-2; PP2A

**INTRODUCTION**

In hematopoietic stem/progenitor cells, the interferon-inducible, double-stranded RNA-dependent protein kinase, PKR (protein kinase R), is a central mediator for the antiproliferative effects of a wide range of hematopoietic cellular stresses including viral infection, hematopoietic growth factor deprivation, inflammatory cytokines, Toll-like receptor ligands and chemotherapy treatment. Once activated by cellular stress, PKR inhibits proliferation and initiates apoptosis by phosphorylation of eukaryotic initiation factor 2α (eIF2α) to inhibit new protein synthesis, inhibition of B-cell lymphoma 2 (Bcl-2) function and activation of signaling pathways including p38 mitogen-activated protein kinase, nuclear factor-κB, p53 and signal transducer and activator of transcription 1. Loss of PKR expression/activity has been associated with more aggressive human breast carcinoma, non-small-cell lung cancer and various acute and chronic leukemias including B-cell chronic lymphocytic leukemia and T-cell acute lymphoblastic leukemia. In addition, although PKR expression has been reported to be increased in some solid tumors such as breast, PKR activity is inhibited either directly or indirectly in these cells, resulting in prosurvival conditions. Taken together, these findings suggest that loss of PKR is an important driver of tumorigenesis.

Deregulation of apoptosis is a major contributor to the development of malignant phenotype and chemoresistance in hematopoietic cells. Importantly, it has been reported that loss of PKR activity may lead to deregulation of apoptosis that promotes and/or maintains the malignant phenotype, but the mechanism remains unclear. Recently, protein phosphatase 2A (PP2A) was reported to be a substrate of PKR, and PP2A activation has been reported to regulate the intrinsic apoptosis pathway by directly dephosphorylating Bcl-2. As studies indicate that PP2A-mediated dephosphorylation of Bcl-2 is critical to initiate apoptosis, and Bcl-2 is commonly overexpressed in hematologic malignancies, we focused our studies on elucidating the role for PKR in regulating apoptosis in human leukemia cells. Significantly, our results indicate that expression of enzymatically active PKR is required for PP2A activation and apoptosis in response to cellular stress including hydrogen peroxide (H2O2) or doxorubicin (DOX) treatment. Furthermore, cells with reduced PKR activity display increased phosphorylated Bcl-2, increased association of Bcl-2 with Bax, reduced Bax insertion into the outer mitochondria membrane (OMM) and enhanced survival following stress treatment. A xenograft model of human leukemia demonstrates that acute leukemia cells with reduced PKR proliferate more rapidly and are resistant to chemotherapy in vivo. These results establish that the PKR/PP2A signaling axis negatively regulates leukemia progression and is required for sensitivity of leukemia cells to chemotherapy in vitro and in vivo.

**MATERIALS AND METHODS**

Cell lines, antibodies and other reagents

REH and K562 cells were obtained from ATCC (Manassas, VA, USA) and propagated in RPMI-1640, 10% fetal bovine serum, 1% l-glutamine and 1% penicillin–streptomycin in a humidified incubator at 37°C and 5% CO2 (Life Technologies, Carlsbad, CA, USA). In addition, medium for Sicontrol or SiPKR cells contained 2 μg/ml puromycin (Sigma-Aldrich, St Louis, MO, USA).

Dr W Stratford May, Department of Medicine, Division of Hematology and Oncology, University of Florida, 2033 Mowry Road, Box 103633, Gainesville, FL 32610, USA.

E-mail: smay@ufl.edu

These authors contributed equally to this work.

Received 4 July 2013; revised 21 July 2013; accepted 24 July 2013
MO, USA) and medium for Sicontrol or SIPKR cells carrying luciferase contains both 2 μg/ml puromycin and 200 μg/ml hygromycin. DOX and PKR inhibitor compound (PKRI) were from Calbiochem/EMD Millipore (Darmstadt, Germany). FTY720 was from Cayman Chemical Company (Ann Arbor, MI, USA) and okadaic acid was from Millipore (Billerica, MA, USA). Hydrogen peroxide was from Sigma-Aldrich. Phospho-threonine 325-specific PKR rabbit polyclonal antibody was from Invitrogen/Biosource (Darmstadt, Germany). FTY720 was from Cayman Chemical Company (Ann Arbor, MI, USA) and okadaic acid was from Millipore (Billerica, MA, USA).

Inhibition of PKR expression by siRNA

Transduction-ready lentivirus particles containing small interfering RNAs (siRNAs) specific for human PKR were used to knockdown PKR expression in REH and K562 cells according to the manufacturer’s protocol (Santa Cruz Biotechnology, Inc., sc-36263). A green fluorescent protein-expressing lentivirus was used to measure transduction efficiency and optimize conditions. After transduction, stable cell lines were selected with 2 μg/ml puromycin. Efficiency of knockdown was evaluated by western blotting.

Cell apoptosis and survival assay

Cells were treated with varying doses and times of DOX or H2O2, and apoptosis analyzed by annexin V staining using an annexin V-phycocyanin (PE) apoptosis detection kit I according to the manufacturer’s protocol (BD Biosciences, San Jose, CA, USA). Stained cells were analyzed by FlowJo (Ashland, OR, USA). Alternatively, cells were treated with varying doses and times of DOX or H2O2, and apoptosis determined by measuring free phosphate in solution. PP2A activity (pM units) was measured using a PP2A phosphatase assay (Millipore). PP2A activity was measured using a PP2A phosphatase assay (Millipore).

RESULTS

Loss of PKR inhibits apoptosis and promotes survival in response to cellular stress

To test the role of PKR on human leukemic cell growth, both lymphoid REH and myeloid K562 leukemic cells were transduced with lentivirus containing either a PKR SiRNA (SIPKR) or a control scrambled sequence SiRNA (Sicontrol). Importantly, similar transduction and selection efficiencies were observed using either siPKR or siControl expressing lentivirus (data not shown). Significant (>90%) reduction of PKR expression in SiPKR compared with siControl cells was confirmed by western blot (Figure 1a). Importantly, cell proliferation rates were unaffected by PKR knockdown under normal (nonstress) conditions (Figure 1b).

To better characterize the role of PKR on cell survival during stress, cells were exposed to increasing concentrations of either H2O2 or the antileukemic agent, DOX for 48 h. Cell survival and apoptosis was measured by annexin V staining. Significantly, reduced PKR expression in both K562 and REH cells delays the rate and extent of apoptosis (Figure 1e). For instance, following treatment of REH cells with 200 μM H2O2 for 48 h, SIPKR cells have a 33% decrease in apoptosis (P < 0.01) compared with control cells (Figure 1f). In addition, PKR knockdown cells exposed to H2O2 for 15 min at 80 000 × g at 4 °C. The pellet was collected and proteins analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting. Purity of mitochondria isolated was determined using a COX (Cell Signaling Technology) antibody to identify intramitochondrial contents and an HSP90 antibody (Santa Cruz Biotechnology Inc.) to detect cytoplasmic contaminants.

Xenograft studies

All studies were approved by the University of Florida institutional animal care and use committee. On the day of tumor inoculation, NOD/SCID/IL2r-γnull (NSG) mice received 200 μg of total body irradiation at a dose rate of 325 cGy/min. Immediately following irradiation, 10 million REH Sicontrol or REH SIPKR cells suspended in 100 μl RPMI-1640 were injected through tail vein. For 3 days before irradiation and 14 days post irradiation, animals were given Sulfatrim antibiotic water. In the treatment group, mice were given a single dose of DOX (5 mg/kg) intravenously 3 days after inoculation. In the placebo group, mice were given equivalent volume of normal saline. In the group treated with both DOX and FTY720, FTY720 was given at 2 mg/kg/day intraperitoneally from day 1 to day 14 following irradiation. After inoculation of leukemia cells, mice were evaluated daily by veterinary staff and mice with a body condition score of < 2 were killed.

Starting 2 weeks post inoculation, tumor burden was monitored weekly using an IVIS Lumina II In Vivo Imaging System (Xenogen, Alameda, CA, USA). On the day of imaging, mice were given 150 mg/kg D-luciferin intraperitoneally 10 min before imaging, anesthetized with isoflurane and subjected to imaging.

At 6 weeks after irradiation, moribund mice were killed and bone marrow harvested from femurs. Cells were stained with anti-human CD45-PE/anti-mouse CD45 FITC (eBioscience, San Diego, CA, USA) and the percentage of human CD45+ mouse CD45− cells was measured by flow cytometry or subjected to western blotting for detection of PKR levels.

Statistics

All data are presented as the mean ± s.d. Significant differences were determined by t-test using SPSS Statistics Premium software (IBM, Armonk, NY, USA). Kaplan–Meier curve of overall survival of mice was plotted and analyzed by Graphpad Prism 6 software (Graphpad software, La Jolla, CA, USA). The criterion for a statistical significance is P < 0.05.
PKR inhibits leukemogenesis by PP2A activation

X Cheng et al

Figure 1. Loss of PKR inhibits apoptosis and promotes survival in response to cellular stress. (a) REH and K562 cells were transduced with lentivirus expressing either PKR SiRNA (SiPKR) or scrambled control SiRNA (Sicontrol). Knockdown of PKR expression was confirmed by western blot. (b) 0.4 × 10^6 of both Sicontrol and SiPKR cells were cultured for 5 days and cell numbers were counted daily. (c, d) REH or K562 cells were subjected to transwell assay. Invasion across basement membrane was analyzed. (e) Cells were exposed to various concentrations of H₂O₂ or DOX for 48 h and apoptosis evaluated by flow cytometry using annexin V-PE and 7-AAD staining. (f) REH cells were treated with either 100 μM H₂O₂ or 400 nM DOX, and K562 cells were exposed to 400 μM H₂O₂ or 1500 nM DOX. Apoptosis assays were performed at designated time points (0, 24, 48 and 72 h) by flow cytometry. All results are representatives of three independent experiments. *Indicates P < 0.05.

© 2013 Macmillan Publishers Limited
up to 72 h demonstrate a 20–25% decrease in apoptosis compared with control cells (Figure 1f). Similarly, PKR knockdown cells treated with DOX for 72 h have a 33 and 22% decrease in apoptosis compared with Sicontrol cells (Figure 1f). These results indicate that PKR is required for the full and potent effect of an oxidative or chemotherapeutic stress application that can initiate apoptosis.

Suppression of PKR inhibits PP2A activity and increases Bcl-2 phosphorylation and resistance to apoptosis

As decreased PKR expression inhibits stress-induced apoptosis, we examined the mechanism by which PKR may regulate apoptosis in leukemic cell lines. Significantly, although Bcl-2 expression is not affected by reduced PKR, Bcl-2 phosphorylation at serine 70 (p-S70-Bcl-2) is significantly increased, indicating one mechanism by which loss of PKR may enhance cell survival (Figure 2a).

As we previously reported that the protein phosphatase PP2A is a direct negative regulator of Bcl-2, we measured PP2A activity in cells with reduced PKR or treated with a specific small-molecule PKR inhibitor (PKRI). Importantly, PP2A activity is significantly decreased to ~60% of control cells in cells with reduced PKR, whereas the level of PP2A/C expression does not change (Figures 2a and b). Furthermore, when cells are treated with increasing concentrations of PKRI, phospho-PKR (a measure of enzymatic activation) phosphorylation of the PKR substrate eIF2α and PP2A activity are decreased, confirming their upstream regulation by PKR (Figure 2d). In addition, although total PP2A or Bcl-2 expression is not altered, Bcl-2 phosphorylation is markedly increased upon treatment with PKRI (Figure 2c). These results indicate that PKR catalytic activity is required to activate PP2A that results in dephosphorylation of Bcl-2. This may explain, at least in part, why cells with reduced PKR activity display enhanced survival.

Activation of PP2A restores chemosensitivity to cells expressing decreased PKR

As PKR-dependent PP2A activation may be necessary for the full and potent initiation of apoptosis, we investigated whether direct activation of PP2A can restore sensitivity of cells with decreased PKR to DOX or H₂O₂. For these studies, the specific PP2A activator FTY720 that has been reported to have antileukemic activity in vitro and in vivo was tested. As a control, we used the PP2A inhibitor, okadaic acid. Importantly, we tested various concentrations of FTY720, to determine an optimum concentration (2.5 μM) that increases PP2A activity by approximately 50% but does not affect REH or K562 cell viability under normal growth conditions for use in subsequent studies (data not shown and Figure 3a). As expected, results demonstrate that treatment of cells with FTY720 decreases, whereas treatment with okadaic acid increases Bcl-2 phosphorylation (Figure 3b). Significantly, FTY720 treatment of PKR knock-down cells restores H₂O₂ and DOX sensitivity to levels comparable with siControl cell (Figures 3c and d).

Loss of PKR stabilizes Bcl-2/Bax association and inhibits Bax insertion into the OMM

As PKR-dependent PP2A activation may be required for Bcl-2 dephosphorylation, which induces apoptosis, we investigated...
whether PKR may affect the function of Bcl-2 to associate with Bax and regulate the proapoptotic function of Bax of insertion into the OMM. Following treatment with H$_2$O$_2$, the Bcl-2/Bax complex was reciprocally co-immunoprecipitated from cells that express either a SiPKR or control siRNA. Significantly, in both REH and K562 cells, reduced PKR expression was discovered to increase the association of Bcl-2 and Bax following treatment with H$_2$O$_2$ (Figures 4a and b).

Next, we isolated whole mitochondria from cells following treatment with H$_2$O$_2$ to measure the level of Bax insertion into the OMM. In either Sicontrol REH or K562 cells, Bax insertion into the OMM increases in a dose-dependent manner upon treatment with H$_2$O$_2$ (Figures 4c and d). In contrast, cells with decreased PKR expression display a significantly reduced level of Bax insertion into the OMM following stress.

Decreased PKR enhances the extent and chemoresistance of leukemia in vivo

To test whether the loss of PKR expression affects leukemia cell spread and survival in vivo, we monitored leukemic tumor load in a mouse xenograft model and compared results with mouse survival. NSG mice were engrafted with either $1 \times 10^6$ SipKR or Sicontrol cells that express a luciferase reporter. The Sicontrol and SipKR cells used were confirmed to have comparable bioluminescence signals (data not shown). Following engraftment, imaging of mice was performed weekly and to quantify leukemia tumor burden (Figure 5a). Significantly, xenografted mice receiving SipKR cells display an increased rate of tumor spread compared with Sicontrol xenografts (Figure 5b). For example at 4 weeks following inoculation, mice receiving siPKR cells display approximately twofold more leukemic cell burden than mice receiving Sicontrol cells (Figure 5b).

Next, we examined whether reduced expression of PKR in xenografted leukemic cells may affect the efficacy of DOX treatment in vivo. Briefly, xenografts were established for 3 days at which time mice received a single intravenous dose of either vehicle or 5 mg/kg DOX. The rate of tumor spread was compared to evaluate the response to treatment. Significantly, xenografts with SiPKR cells were less sensitive to DOX treatment in contrast to xenografts of Sicontrol cells (Figure 5b).

Finally, we tested whether activation of the PKR/PP2A signaling axis may restore sensitivity to chemotherapy of mice xenografted with cells that have reduced PKR expression. Briefly, 3 days following engraftment, mice were administered a single dose of DOX as above followed by daily injection with FTY720 at 2 mg/kg for 2 weeks. Mice that received both DOX and FTY720 displayed a significantly decreased leukemia cell burden compared with mice treated with DOX alone (Figure 5c). Thus, co-treatment with FTY720 and DOX results in an almost twofold reduction in sensitivity to a single treatment with DOX in vivo.

The overall survival of mice in each group was evaluated by Kaplan–Meier analysis (Figure 5d). Consistent with increasing
tumor burden in mice xenografted with SI PKR cells, these mice also have significantly shorter survival compared with mice inoculated with SIControl cells ($P = 0.0042$). Furthermore, although the survival of mice in both groups could be prolonged following a single treatment with DOX, survival is significantly increased for mice engrafted with SIControl cells compared with those engrafted with PKR knockout leukemic cells ($P = 0.0021$ vs $P = 0.1037$). Importantly, survival of SI PKR engrafted mice following treatment with the combination of FY720 and DOX is also significantly increased over DOX-only-treated mice ($P = 0.0164$). This suggests that reactivation of the PKR/PP2A pathway in leukemic cells displaying reduced PKR may restore sensitivity to antileukemic treatment.

To confirm that inoculated leukemia cells did engraft bone marrow (the pathological initiation site of leukemia development), both human and mouse CD45+ cells were quantified after isolation from bone marrow of xenografted mice. Importantly, all moribund mice analyzed displayed over 90% human CD45+ leukemia cells in their bone marrow (Figure 5e). In addition, western blot analysis of bone marrow cells isolated from moribund mice confirmed that the REH SI PKR leukemic cells continued to display reduced expression of PKR at the time of death (Figure 5f).

**DISCUSSION**

Our findings demonstrate that activity of the interferon-inducible double-stranded RNA-dependent protein kinase PKR may inhibit human leukemic cell growth and promote sensitivity to chemotherapy or other stress applications including direct oxidative stress. Significantly, K562 or REH cells with reduced PKR expression or those treated with PKRI display decreased substrate phosphorylation of eIF2z, decreased PP2A activity, increased Bcl-2 phosphorylation and reduced apoptosis following treatment with either DOX or H2O2. In addition, inhibition of PKR activity promotes Bcl-2/BAX association and inhibits BAX insertion into the OMM.37 Significantly, and of potential clinical relevance, we find for the first time that mice xenografted with leukemia cells that have reduced PKR display an increased rate of tumor spread compared with control xenografts, and treatment with FY720, a PP2A activator, can rescue this phenotype. In addition, increased chemosensitivity of FY70-treated cells occurs in close association with decreased Bcl-2 phosphorylation and enhanced apoptosis. Taken together, these data indicate that decreased PKR activity in human acute leukemia cells may inhibit the initiation of apoptosis and promote leukemogenic survival by a mechanism dependent, at least in part, on PP2A activation and Bcl-2 dephosphorylation. This notion is further supported by our preliminary results using Reverse Phase Protein Array (RPPA) analysis of CD34+ leukemic cells from 511 acute myeloid leukemia patient samples that indicate that PKR expression and activity is significantly decreased in acute myeloid leukemia blast cells compared with the CD34+ cells from healthy donors (RL Bennett, SM Kornblau and WS May; data not shown). Thus, decreased PKR expression and activity may be a common theme in acute leukemia and, if this is the case, may point the way to novel therapeutic strategies for such patients.

Importantly, we found that loss of PKR expression potentiates leukemia cell survival following chemotherapy treatment in vivo. Recently, we reported that PKR-null mice and mice expressing a catalytically null, dominant-negative PKR transgene (specifically in hematopoietic cells) have increased numbers of hematopoietic stem/progenitor cells in association with increased peripheral blood cell counts as the mice age.6 Significantly, the loss of PKR activity in bone marrow cells from these mice promoted an increased frequency of hematopoietic stem/progenitor cells as evidenced by more robust hematopoietic colony formation and enhanced resistance to apoptosis following hematopoietic growth factor deprivation, treatment with inflammatory cytokines or irradiation.8 Now, findings here extend these results by demonstrating that xenografts of REH acute lymphoblastic leukemia cells with reduced PKR display a significantly greater rate of engraftment and reduced overall survival than control cell xenografts. Significantly, tumor volume following 4 weeks of engraftment is more than double in mice engrafted with REH-SI PKR cells versus SIControl cells, and SI PKR xenografts are more resistant to DOX treatment compared with SIControl xenografts. Together, these results lead us to propose that downregulation of...
PKR activity in xenografted cells may promote leukemogenesis and chemoresistance because of reduced sensitivity of these cells to proapoptotic stress such as growth factor deprivation or exposure to inflammatory cytokines. In support of this and consistent with the *in vitro* results, sensitivity of SiPKR xenografts to DOX can be 'rescued' by treatment with the PP2A activator, Sicontrol.

**Figure 5.** In leukemia xenografts, reduced expression of PKR promotes tumor progression and chemoresistance. Reactivation of the PKR/PP2A signaling axis by FTY720 treatment rescues chemosensitivity. (a) NSG mice were divided into five experiment groups (Sicontrol no treatment, Sicontrol DOX treatment, SiPKR no treatment, SiPKR DOX treatment and SiPKR DOX + FTY720 treatment) and inoculated with REH cells (Sicontrol or SiPKR) carrying luciferase gene followed by corresponding intervention in each group. Tumor progression was monitored by weekly *in vivo* imaging. (b) Tumor progression is evaluated and compared in untreated groups between mice carrying REH Sicontrol cells and mice carrying REH SiPKR cells. (c) Tumor progression following 5 mg/kg DOX treatment (as described in the Materials and methods section) in mice carrying either Sicontrol or SiPKR cells is evaluated and compared. Mice engrafted with REH SiPKR cells were also treated with same dose of DOX plus 2 mg/kg daily FTY720 for 2 weeks, tumor progression was evaluated and compared with mice carrying same leukemic cells but treated with only DOX. (d) Kaplan–Meier curve of overall survival of mice in each group was plotted. (e) Bone marrow cells from moribund mice carrying leukemia were harvested and stained with both human and mouse CD45 antibody, and the results were analyzed by flow cytometry. (f) Bone marrow cells from moribund mice carrying leukemia were harvested and lysed. PKR expression was evaluated by western blot. *Indicates $P<0.05$. 

© 2013 Macmillan Publishers Limited
FTY720. Thus, reduced PP2A activation delays activation of the intrinsic mitochondria apoptotic mechanism and may, at least in part, account for the greater rate of engraftment observed for leukemic cells expressing reduced PKR.

Alternatively, our findings indicate that decreased PKR expression promotes cell invasion of hematologic cell lines in vitro that may contribute to the increased extent of engraftment and increased tumor volume displayed by REH siPKR cells. However, in preliminary studies, we did not detect any PKR-dependent changes in expression of genes important for cell invasion/migration (data not shown). Furthermore, our findings here and those previously published indicate that PKR is necessary and sufficient to initiate apoptosis in response to growth factor starvation. Thus, we believe we can attribute the effect of PKR on cell invasion to increased survival of cells with reduced PKR. Interestingly, we previously reported that decreased PKR inhibits
PKR inhibits leukemogenesis by PP2A activation
X Cheng et al

Potentially of clinical significance, the results demonstrate that reactivation of the PKR/PP2A axis in cells with reduced PKR activity by treatment with the PP2A activator FTY720 restores sensitivity of leukemic cells to DOX, an important standard of care treatment in induction of acute leukemia. Interestingly, FTY720 is a shingosine 1-phosphate (S1P) receptor modulator that has already been used in clinical trials to treat relapsing multiple sclerosis and to prevent organ rejection following renal transplantation.38,39 In addition, others have reported FTY720 as a potential antileukemic drug both in vitro and in vivo but the mechanism is not clear. Now, our results confirm that FTY720 may activate PP2A, which is frequently inhibited in hematopoietic malignancies.40 Significantly, as reduced PKR may frequently occur in acute leukemias and our findings here suggest that loss of PKR leads to reduced PP2A activity, a ‘PP2A activation strategy’ might be envisioned to therapeutically enhance leukemia therapy in patients whose tumors display reduced PKR activity. This notion is supported by our findings here that FTY720 more effectively enhances apoptosis induced by H2O2 or DOX in human leukemic cells displaying reduced PKR expression than control cells. Therefore, PKR expression/activity may serve as a predictor of effectiveness of FTY720 treatment. In addition, although previous studies test FTY720 solely as an antileukemia agent, our study for the first time combines it with DOX both in vitro and in vivo. In this manner, we were able to treat leukemic cells with a considerably lower dosage of FTY720 that stimulates PP2A activation but does not by itself significantly affect cell proliferation or survival. This indicates that FTY720 may be useful in combination with cytotoxic chemotherapy treatments like doxorubicin to facilitate their antileukemic effect while avoiding potential serious side effects from full-dose FTY720 treatment.

Taken together, our results demonstrate that loss of PKR function contributes to leukemia disease progression because of defects in the intrinsic apoptosis mechanism. In the future, loss of PKR activity may serve as a useful clinical predictor of chemoresponsiveness to DOX-containing regimens and/or sensitivity to FTY720. Importantly, reactivation of the PKR/PP2A signaling axis may serve as a novel therapeutic approach to enhance response to chemotherapy, especially in leukemia with low PKR activity.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We thank Tammy Flagg for technical assistance. This work was supported by NIH/NIHBLI R01 HL054083.

AUTHOR CONTRIBUTIONS
XC and RLB designed experiments, performed research and wrote the manuscript; XL and MB performed experiments; and WSM designed experiments and wrote the manuscript.

REFERENCES
1 Ito T, Jagsz R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91: 7455–7459.
2 Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 2006; 108: 821–829.
3 Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004; 428: 341–345.
4 Li YJ, Zheng JM, Huang SF, Wang XZ, Zhao SQ, Bai WJ et al. Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR. Int J Mol Med 2008; 21: 215–222.
5 Murad JM, Tone LG, de Souza LR, De Lucca FA. A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis 2005; 34: 1–5.
6 Liu X, Bennett RL, Cheng X, Byrne M, Reinhard MK, May Jr WS. PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. Blood 2013; 121: 3364–3374.
7 Bennett RL, Pan Y, Christian J, Hui T, May Jr WS. The RAX/PACT-PKR stress pathway promotes p53 sumoylation and activation, leading to G1 arrest. Cell Cycle 2012; 11: 407–417.
8 Ruvolo VR, Kurinna SM, Kameeji KB, Schuster TF, Martelli AM, McCubrey JA et al. PKR regulates B56alpha-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem 2000; 275: 35474–35485.
9 Deb A, Haque SI, Mogensen T, Silverman RH, Williams BR. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 2001; 166: 6170–6180.
10 Goh KC, deVeere MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J 2000; 19: 4292–4297.
11 Abraham N, Jaramillo ML, Dunsifer PI, Icely PL, Stojdl DF et al. The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia. Exp Cell Res 1998; 244: 394–404.
12 Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in Sq- associated leukemias. Oncogene 1996; 12: 1593–1596.
13 Blalock WL, Bavelotti A, Piazzo M, Faenza L, Cocco L. A role for PKR in hematologic malignancies. J Cell Physiol 223: 572–591.
14 Hii SI, Hardy L, Cough T, Payne EJ, Grimmett K, Gill D et al. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 2004; 109: 329–335.
15 Yeung MC, Liu J, Lau AS. An essential role for the interferon-endo, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996; 93: 12451–12455.
16 Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L et al. Prognostic significance of reduced PKR expression in chronic myeloid leukaemia. Int J Clin Cancer Res 2010; 16: 5522–5528.
17 Savinova O, Joshi B, Jagus R. Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells. Int J Biochem Cell Biol 1999; 31: 175–189.
18 Bennett RL, Currathurs AL, Hui T, Kenney KR, Liu X, May Jr WS. Increased expression of the dsRNA-activated protein kinase in breast cancer promotes sensitivity to doxorubicin. PLoS One 2012; 7: e46040.
19 Kim SH, Forman AP, Mathews MB, Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase PKR, Oncogene 2000; 19: 3086–3094.
20 Barber GN, Wambach M, Thompson S, Jagsz R, Katze MG. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol 1995; 15: 3138–3146.
21 Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 1995; 14: 3828–3834.
22 Meurs EF, Galabru J, Barber GN, Katze MG. Protein kinase PKR is modulated by IRF-1 and is reduced in 5q- associated leukemias. Exp Hematol 2004; 32: 428–429.
23 Zheng T, Johnson CD, Coleman AJ, Bui H, Bui H, Bui H. The protein kinase PKR inhibits leukemogenesis by PP2A activation

© 2013 Macmillan Publishers Limited
Blood Cancer Journal
29 May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865–26870.

30 Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277: 22847–22852.

31 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408–2421.

32 Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303–1312.

33 Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27: 159–168.

34 Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One 2012; 7: e36429.

35 Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 2012; 113: 1314–1322.

36 Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988; 256: 283–290.

37 Mai H, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 2003; 278: 1886–1891.

38 Ettenger R, Schmouder R, Kovarik JM, Bastien MC, PF Hoyer. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. Pediatr Transplant 2011; 15: 406–413.

39 Fazekas F. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr 2012; 162: 354–366.

40 Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013; 335: 9–18.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/